1 / 34

Stöver Lehmann Consulting

Stöver Lehmann Consulting. By Manon St över Matthieu Lehmann Lausanne, June 23 rd 2006. Agenda. Who are we ? Why are we here today ? What has been done until today? What can be achieved and how?. SLC – Team presentation. Manon Stöver Co-founder

tatyana-gaines
Download Presentation

Stöver Lehmann Consulting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Stöver Lehmann Consulting By Manon Stöver Matthieu Lehmann Lausanne, June 23rd 2006

  2. Agenda • Who are we ? • Why are we here today ? • What has been done until today? • What can be achieved and how? Stöver Lehmann Consulting

  3. SLC – Team presentation • Manon Stöver • Co-founder • Expertise in investment within the Petroleum Industry • Matthieu Lehmann • Co-founder • Expertise in Biotechnologies and Process Development Stöver Lehmann Consulting

  4. SLC - Philosophy • Our orientation is to raise funds for refreshing and interesting research and development • Our vision is to support ideas with huge potential for humanity • We are looking for revolution more than evolution Stöver Lehmann Consulting

  5. SLC – Past Successes • SLC’s past successes in raising funds are in the field of research and development: • BioXell (Cancer therapy) • 7TM Pharma (Virology) • H2FUEL (hydrogen engine) • HydroNEXT (biofuel cell) Stöver Lehmann Consulting

  6. Dr. de Grey’s presentation • Engineering background from computer sciences • Previous work in bioinformatics • Current research in biogerontology • His vision: Reengineering the approach of how to cure aging Stöver Lehmann Consulting

  7. Gerontology Engineering Geriatrics Metabolism Damage Pathology What is Unlimited Life? • A research institute in biogerontology • A concept: Curing aging • The final mission of UL is to provide people with medecines to cure aging Stöver Lehmann Consulting

  8. More about Unlimited Life • Home institution for research is Cambridge • Research is highly potential for several breakthroughs : ‘We are already on the road, it’s definitely more than a simple concept !’ • Absolutely refreshing approach of anti-aging process: start at the roots of the process • At the beginning of something revolutionary Stöver Lehmann Consulting

  9. The 7 deadly things principle • Basics of Dr. de Grey research • Damages rising with age • Cell loss, cell atrophy • Nuclear [epi]mutations (only cancer matters) • Mutant mitochondria • Death-resistant cells • Extracellular crosslinks • Extracellular junk • Intracellular junk Stöver Lehmann Consulting

  10. Today’s Focus • Advise to improve funding of Unlimited Life research Why are we concerned ? • We believe in our customer competencies • We may change the world • Aging is the most fatal and the first cause of death on Earth • Life is a gift, we must fight to keep it as hard as we fight for our freedom Stöver Lehmann Consulting

  11. Competitive Anti-Aging Researches • Current technologies to slow the aging process • Cryonic therapy • Chemical drugs (DHEA) • Medicines based on proteins • Plastic surgery • Vitamins and food supplements Stöver Lehmann Consulting

  12. Results for current Anti-Aging • Results obtained from research • Slowing down the process of aging • Mask the external signs of aging • Small improvement on the origin of aging process • None of these technology treated aging from its roots • NB! These technologies are not competitive with the results of Dr. de Grey’s research Stöver Lehmann Consulting

  13. Origin of previous raised funds • Past funds • Winning the Mprize: donations for continuing research • Expenses contributions • Donation of Air miles • Who are these investors ? • Individuals • Foundations Stöver Lehmann Consulting

  14. Money raised from these funds • Funds raised • Mprize: $ 3.5 million • Donations: $ 218’005 • Cost expenses: $ 89’756 • Air miles: 360’374 miles Good starting point but obviously not enough ! Stöver Lehmann Consulting

  15. Dr. de Grey’s request for funding • Dr. de Grey objectives: • $100M/year of funding for the next 10 years • Creating research institutes all over the world • Investors are not to draw any direct benefit from providing funding Stöver Lehmann Consulting

  16. Possible solutions • Organizational improvements • Promotion improvements • Improvement of current funding ways • New funding ways Stöver Lehmann Consulting

  17. Organizational improvements • Organizational aspect • Define milestones/targets • Build a team • Find a ‘face’ for funding leader Stöver Lehmann Consulting

  18. Promotion improvements • Generate publicity • Newspapers • Broadcasting of documentaries • Universities • Advertisements • Exhibition • Nobel price for medicine Stöver Lehmann Consulting

  19. Improvement of current funding ways • Donations • Other foundations • Individuals • Air miles Stöver Lehmann Consulting

  20. Foundations and Individuals • Aim at other foundations: • AIDS association • Cancer therapy association • Arthritis Foundation • Biological Trust • Convince individuals: • Wealthy philanthropic people Stöver Lehmann Consulting

  21. Airmiles Change the law • Airline companies might write off their airmiles older than 20y to foundations • Opportunity to raise billions of airmiles • Very convenient for both parties Stöver Lehmann Consulting

  22. New funding ways • Business Angels • Open source research • Partnerships • VCs Stöver Lehmann Consulting

  23. Business angels • With certain characteristics: • High personal interest in the research • Diversifying his/her investments • Maybe (s)he will give a billion • Examples • Donald Trump • Hugh Hefner • Bill Gates • Larry Ellison Stöver Lehmann Consulting

  24. Larry Ellison • Founder of Oracle • Almost as wealthy as Bill Gates • Human benefactor • What is more prestigious than investing in first cause of death Stöver Lehmann Consulting

  25. Open source • No profits involvement • Access to a huge community • Low and shared cost • Increase in time efficiency and productivity • High demanding process from a controlling aspect Stöver Lehmann Consulting

  26. Open source in our case • Applicable on secondary level of research • Set up an association with confidential agreement • Create different virtual institutes around the world Stöver Lehmann Consulting

  27. Partnership • Partners • Cooperation in research; such as Cryogenics • Set up subsidiaries with pharmaceuticals • VCs with pharmaceuticals in the portfolio • Business angels with certain interests • To attract partners: certain level of leverage needed • Define milestones/targets • Create a source of revenues Stöver Lehmann Consulting

  28. Venture Capitalist • Involvement in the management and the ownership • Huge amount money can be brought on the table • Examples • Cardinal Partners • Polaris Venture Partners • Techno Venture Management • Novartis Bioventures Fund • Cargill Ventures Three Arch Partners Stöver Lehmann Consulting

  29. Funding schedule First two years • Research set up • Define milestones/targets for third parties • Alliances with anti-aging clinics to set up globally research institutes at universities • Create a team • Use of benefits of an open source research • Funds • Foundations and prices • Business Angels • Adjust budget Stöver Lehmann Consulting

  30. Funding schedule Next three years • Involvement of VCs • Creating revenues (seminars, meetings, publishing books, magazines) • Partnership with pharmaceutical companies regarding first mover advantage for commercial use Stöver Lehmann Consulting

  31. Financial Scheme - Sources Stöver Lehmann Consulting

  32. Financial scheme - Uses Stöver Lehmann Consulting

  33. Conclusion • We have investigated possibilities for funding • within the requests • outside the requests • Who dares wins… Stöver Lehmann Consulting

  34. Thank for your attention Manon Stöver: manonstover@gmail.com Matthieu Lehmann matthieu.lehmann@epfl.ch

More Related